YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages

Toxicology and Applied Pharmacology

Volumn 260, Issue 2, 2012, Pages 193-200

  Hwang, Tsong Long ^a,b   Tang, Ming Chi ^a   Kuo, Liang Mou ^c   Chang, Wen De ^a   Chung, Pei Jen ^a   Chang, Ya Wen ^a   Fang, Yao Ching ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Alveolar macrophage; cAMP; cGMP; Nitric oxide; Phosphodiesterase; YC 1

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; DACTINOMYCIN; FORSKOLIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIFICIGUAT; NITRIC OXIDE; PROSTAGLANDIN E1; ROLIPRAM;

ANIMAL CELL; ARTICLE; CELL LYSATE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYMATIC DEGRADATION; ENZYME INHIBITION; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; OXIDATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DINOPROSTONE; ENZYME ACTIVATORS; FORSKOLIN; GUANYLATE CYCLASE; IMMUNOBLOTTING; INDAZOLES; ISOQUINOLINES; LUNG DISEASES; MACROPHAGES, ALVEOLAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORIC DIESTER HYDROLASES; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES;

RATTUS;

EID: 84862814591     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.02.011     Document Type: Article

References (56)

1. Afshari A., Brok J., Moller A.M., Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst. Rev. 2010, CD002787.
2. Altarejos J.Y., Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat. Rev. Mol. Cell Biol. 2011, 12:141-151.
3. Barnes P.J., Dweik R.A., Gelb A.F., Gibson P.G., George S.C., Grasemann H., Pavord I.D., Ratjen F., Silkoff P.E., Taylor D.R., Zamel N. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010, 138:682-692.
4. Chen C.C., Chiu K.T., Sun Y.T., Chen W.C. Role of the cyclic AMP-protein kinase A pathway in lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages. Involvement of cyclooxygenase-2. J. Biol. Chem. 1999, 274:31559-31564.
5. Chen C.J., Hsu M.H., Huang L.J., Yamori T., Chung J.G., Lee F.Y., Teng C.M., Kuo S.C. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem. Pharmacol. 2008, 75:360-368.
6. Chi D.S., Qui M., Krishnaswamy G., Li C., Stone W. Regulation of nitric oxide production from macrophages by lipopolysaccharide and catecholamines. Nitric Oxide 2003, 8:127-132.
7. Diamant Z., Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm. Pharmacol. Ther. 2011, 24:353-360.
8. Eberhardt W., Pluss C., Hummel R., Pfeilschifter J. Molecular mechanisms of inducible nitric oxide synthase gene expression by IL-1beta and cAMP in rat mesangial cells. J. Immunol. 1998, 160:4961-4969.
9. Essayan D.M. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol. 1999, 57:965-973.
10. Francis S.H., Busch J.L., Corbin J.D., Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62:525-563.
11. Friebe A., Schultz G., Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996, 15:6863-6868.
12. Friebe A., Mullershausen F., Smolenski A., Walter U., Schultz G., Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 1998, 54:962-967.
13. Galea E., Feinstein D.L. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J. 1999, 13:2125-2137.
14. Gantner F., Tenor H., Gekeler V., Schudt C., Wendel A., Hatzelmann A. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J. Allergy Clin. Immunol. 1997, 100:527-535.
15. Garn H., Siese A., Stumpf S., Barth P.J., Muller B., Gemsa D. Shift toward an alternatively activated macrophage response in lungs of NO2-exposed rats. Am. J. Respir. Cell Mol. Biol. 2003, 28:386-396.
16. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs 2000, 59:193-212.
17. Gorska K., Maskey-Warzechowska M., Krenke R. Airway inflammation in chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2010, 16:89-96.
18. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
19. Greenberg S.S., Zhao X., Wang J.F., Hua L., Ouyang J. cAMP and purinergic P2y receptors upregulate and enhance inducible NO synthase mRNA and protein in vivo. Am. J. Physiol. 1997, 273:L967-L979.
20. Gross N.J., Giembycz M.A., Rennard S.I. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010, 7:141-153.
21. Hertz A.L., Bender A.T., Smith K.C., Gilchrist M., Amieux P.S., Aderem A., Beavo J.A. Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21978-21983.
22. Hsieh Y.H., Huang S.S., Day Y.J., Wei F.C., Hung L.M. Involvement of YC-1 in extracellular signal-regulated kinase action in rat cremasteric muscle. J. Pharm. Pharmacol. 2010, 62:1746-1752.
23. Huh J.W., Kim S.Y., Lee J.H., Lee Y.S. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice. Pulm. Pharmacol. Ther. 2011, 24:638-646.
24. Hwang T.L., Wu C.C., Teng C.M. YC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea. Br. J. Pharmacol. 1999, 128:577-584.
25. Hwang T.L., Hung H.W., Kao S.H., Teng C.M., Wu C.C., Cheng S.J. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol. Pharmacol. 2003, 64:1419-1427.
26. Hwang T.L., Wu C.C., Guh J.H., Teng C.M. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway. Biochem. Pharmacol. 2003, 66:149-156.
27. Hwang T.L., Zhuo S.K., Pan Y.L. YC-1 attenuates homotypic human neutrophil aggregation through inhibition of phosphodiesterase activity. Eur. J. Pharmacol. 2008, 579:395-402.
28. Imrich A., Ning Y.Y., Koziel H., Coull B., Kobzik L. Lipopolysaccharide priming amplifies lung macrophage tumor necrosis factor production in response to air particles. Toxicol. Appl. Pharmacol. 1999, 159:117-124.
29. Johnson F.J., Reynolds L.J., Toward T.J. Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram. Toxicol. Appl. Pharmacol. 2005, 207:257-265.
30. Kim S.H., Serezani C.H., Okunishi K., Zaslona Z., Aronoff D.M., Peters-Golden M. Distinct protein kinase A anchoring proteins direct prostaglandin E2 modulation of Toll-like receptor signaling in alveolar macrophages. J. Biol. Chem. 2011, 286:8875-8883.
31. Kleinert H., Pautz A., Linker K., Schwarz P.M. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 2004, 500:255-266.
32. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84:4226-4233.
33. Koarai A., Ichinose M., Sugiura H., Yamagata S., Hattori T., Shirato K. Allergic airway hyperresponsiveness and eosinophil infiltration is reduced by a selective iNOS inhibitor, 1400W, in mice. Pulm. Pharmacol. Ther. 2000, 13:267-275.
34. Laskin D.L., Weinberger B., Laskin J.D. Functional heterogeneity in liver and lung macrophages. J. Leukoc. Biol. 2001, 70:163-170.
35. Lin W.C., Tsai P.S., Huang C.J. Catecholamines' enhancement of inducible nitric oxide synthase-induced nitric oxide biosynthesis involves CAT-1 and CAT-2A. Anesth. Analg. 2005, 101:226-232. (table of contents).
36. McCluskie K., Klein U., Linnevers C., Ji Y.H., Yang A., Husfeld C., Thomas G.R. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J. Pharmacol. Exp. Ther. 2006, 319:468-476.
37. Miotla J.M., Teixeira M.M., Hellewell P.G. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am. J. Respir. Cell Mol. Biol. 1998, 18:411-420.
38. Mulsch A., Bauersachs J., Schafer A., Stasch J.P., Kast R., Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 1997, 120:681-689.
39. Pan S.L., Guh J.H., Peng C.Y., Chang Y.L., Cheng F.C., Chang J.H., Kuo S.C., Lee F.Y., Teng C.M. A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb. Haemost. 2005, 93:940-948.
40. Pautz A., Art J., Hahn S., Nowag S., Voss C., Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010, 23:75-93.
41. Rabe K.F. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 2011, 163:53-67.
42. Redington A.E. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur. J. Pharmacol. 2006, 533:263-276.
43. Sakata D., Yao C., Narumiya S. Prostaglandin E2, an immunoactivator. J. Pharmacol. Sci. 2010, 112:1-5.
44. Schmidt L.M., Belvisi M.G., Bode K.A., Bauer J., Schmidt C., Suchy M.T., Tsikas D., Scheuerer J., Lasitschka F., Grone H.J., Dalpke A.H. Bronchial epithelial cell-derived prostaglandin E2 dampens the reactivity of dendritic cells. J. Immunol. 2011, 186:2095-2105.
45. Serezani C.H., Ballinger M.N., Aronoff D.M., Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am. J. Respir. Cell Mol. Biol. 2008, 39:127-132.
46. Shang L.H., Luo Z.Q., Deng X.D., Wang M.J., Huang F.R., Feng D.D., Yue S.J. Expression of N-methyl-D-aspartate receptor and its effect on nitric oxide production of rat alveolar macrophages. Nitric Oxide 2010, 23:327-331.
47. Shoemark A., Devaraj A., Meister M., Ozerovitch L., Hansell D.M., Wilson R. Elevated peripheral airway nitric oxide in bronchiectasis reflects disease severity. Respir. Med. 2011, 105:885-891.
48. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
49. Sugiura H., Ichinose M. Nitrative stress in inflammatory lung diseases. Nitric Oxide 2011, 25:138-144.
50. Tasaka S., Amaya F., Hashimoto S., Ishizaka A. Roles of oxidants and redox signaling in the pathogenesis of acute respiratory distress syndrome. Antioxid. Redox Signal. 2008, 10:739-753.
51. Tulis D.A. Novel therapies for cyclic GMP control of vascular smooth muscle growth. Am. J. Ther. 2008, 15:551-564.
52. Watts V.J. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J. Pharmacol. Exp. Ther. 2002, 302:1-7.
53. Wohlfart P., Malinski T., Ruetten H., Schindler U., Linz W., Schoenafinger K., Strobel H., Wiemer G. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. 1999, 128:1316-1322.
54. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 1995, 116:1973-1978.
55. Wu C.C., Ko F.N., Teng C.M. Inhibition of platelet adhesion to collagen by cGMP-elevating agents. Biochem. Biophys. Res. Commun. 1997, 231:412-416.
56. Yao C., Sakata D., Esaki Y., Li Y., Matsuoka T., Kuroiwa K., Sugimoto Y., Narumiya S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 2009, 15:633-640.